tweetindex
TH

Breakthrough T1D UK

@BT1DUK · London · joined 25 Feb 2010

We are Breakthrough T1D, formerly known as JDRF, the leading global type 1 diabetes (T1D) research and advocacy charity.

26 293Followers
4 012Following
23 384Posts total
31.4KViews on collected posts

โพสต์ล่าสุด

London, are you ready? 👀 We’re so excited to introduce our incredible speakers for Discovery Day London 2026! Discovery Day offers a welcoming space to connect, learn and share experiences with others living with type 1, no matter where you are on your journey. We’re https:/
757 views · 6 likes · 3 reposts · 0 replies Open on X →
This Friday Fundraiser spotlight is on: our incredible Sit Up Challenge participants! 💙 Earlier this August, 360 people took on 1922 sit ups across the month, inspired by 1922, the year insulin was first used to treat type 1 diabetes (T1D). Together, they raised over £22,000 ht
506 views · 2 likes · 0 reposts · 0 replies Open on X →
Does your family plan on joining us at our Discovery Day in London next Saturday? We'd love to hear from you! 👂 We're looking for families to join us for a quick and informal session, to help us understand the information and support that were most useful to you since https://t
718 views · 1 likes · 3 reposts · 0 replies Open on X →
Get the whole family involved! The 400,000 Step Challenge isn't about finding hours of spare time. It's about making everyday moments count. 🙌 The school run, after-school activities, lunchtime walks and family walk to the park can all help you reach your daily goal. From 6 h
Three people walk through a graffiti-lined underpass, with one person using a white mobility cane. Overlay text reads: “10,000 steps a day for 40 days” and “Take on the 400,000 Step Challenge from 6 October to 14 November and help raise vital funds for T1D research.”
638 views · 5 likes · 1 reposts · 1 replies Open on X →
At the moment, this decision applies to England and Wales. NICE technology appraisal guidance does not automatically apply in Northern Ireland, and there is a separate process in Scotland. We will continue to support conversations in Scotland and Northern Ireland to ensure 449 views · 4 likes · 0 reposts · 0 replies Open on X →
@BT1DUK To understand the real impact and value of this wonderful announcement by NICE, we need to remember that insulin is not a cure. Insulin keeps people with type 1 diabetes alive, for which the world is truly grateful, but it only treats the symptoms of an autoimmune disease 382 views · 6 likes · 1 reposts · 0 replies Open on X →
Today, history has been made: NICE has approved teplizumab for use on the NHS in England and Wales. Teplizumab is the first ever immunotherapy that can delay the onset of type 1 diabetes symptoms for people in the early stages of the condition. For the first time, we’re not
Text graphic announcing teplizumab approval for NHS use in England and Wales by NICE, described as a historic moment, on a soft gradient background.
Informational graphic explaining teplizumab as a first-of-its-kind immunotherapy that can delay the need to take insulin by about three years.
Eligibility graphic stating teplizumab is approved for people over eight with stage 2 type 1 diabetes, on a light purple background.
Text graphic stating Breakthrough T1D UK funded early research and trials leading to teplizumab, highlighting progress in type 1 diabetes treatment and commitment to finding a cure, with logo on a gradient background.
25.5K views · 58 likes · 19 reposts · 4 replies Open on X →
We’re aware of recent media coverage and social discussion around access to hybrid closed loop (HCL) in Scotland. We recognise the concern this is causing, particularly in light of reports about delays or stopped starts. We are in direct conversation with key stakeholders to htt
2.4K views · 5 likes · 5 reposts · 0 replies Open on X →

เทียบกับบัญชีขนาดเดียวกัน

7 โพสต์จาก 90 วันที่ผ่านมา เทียบกับช่วง 10K–100K ผู้ติดตาม ต่ำกว่าบัญชีรุ่นเดียวกันทั้งการเข้าถึงและการมีส่วนร่วม.

ยอดดูมัธยฐาน638บัญชีนี้999ค่ามัธยฐานของ 10K–100K
การเข้าถึง, %2.43%บัญชีนี้3.62%ค่ามัธยฐานของ 10K–100K
การมีส่วนร่วม, %0.89%บัญชีนี้1.92%ค่ามัธยฐานของ 10K–100K
ตัวชี้วัดบัญชีนี้ค่ามัธยฐานของ 10K–100Kอัตราส่วน
ยอดดูมัธยฐานต่อโพสต์6389990.64×
การเข้าถึง (ยอดดู ÷ ผู้ติดตาม)2.43%3.62%0.67×
อัตราการมีส่วนร่วม0.89%1.92%0.46×

บัญชีอื่นในช่วงนี้ →   เปรียบเทียบกับบัญชีอื่น →   ค่าอ้างอิงเหล่านี้คำนวณอย่างไร →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

2.4K22 May
25.5K23 Jun
382
449
6382 Sep
7183 Sep
5064 Sep
757

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.46%22 May
0.34%23 Jun
1.83%
0.89%
1.10%2 Sep
0.56%3 Sep
0.40%4 Sep
1.19%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.92%.

What the audience does

Likes65.9%87 in total
Reposts24.2%32 in total
Replies3.8%5 in total
Quotes4.5%6 in total
Bookmarks1.5%2 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

บัญชีที่คล้ายกัน